

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

- 849** Hopefulness of 'Hope'  
*D S Pisetsky*

**Recommendation**

- 851** EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2  
*R BM Landewé, P M Machado, F Kroon, H WJ Bijlsma, G R Burmester, L Carmona, B Combe, M Galli, L Gossec, A Iagnocco, J D Isaacs, X Mariette, I McInnes, U Mueller-Ladner, P Openshaw, J S Smolen, T A Stamm, D Wiek, H Schulze-Koops*

**Epidemiology**

- 859** Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry  
*M Gianfrancesco, K L Hyrich, S Al-Adely, L Carmona, M I Danila, L Gossec, Z Izadi, L Jacobsohn, P Katz, S Lawson-Tovey, E F Mateus, S Rush, G Schmajuk, J Simard, A Strangfeld, L Trupin, K D Wysham, S Bhana, W Costello, R Grainger, J S Hausmann, J W Liew, E Sirotych, P Sufka, Z S Wallace, J Yazdany, P M Machado, P C Robinson, On behalf of the COVID-19 Global Rheumatology Alliance*

**Rheumatoid arthritis**

- 867** Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD  
*E Ulijn, N den Broeder, M Wientjes, N van Herwaarden, I Meek, L Tweehuysen, A van der Maas, B JF van den Bemt, A A den Broeder*
- 874** Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab  
*I H Shafraan, F Alasti, J S Smolen, D Aletaha*
- 883** Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework  
*S S Zhao, H Lyu, D H Solomon, K Yoshida*

- 891** Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis  
*A Leblond, S Pezet, A Cauvet, C Casas, J Pires Da Silva, R Hervé, G Clavel, S Dumas, S Cohen-Kaminsky, N Bessis, L Semerano, C Lemaire, Y Allanore, J Avouac*
- 901** Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis  
*A Di Matteo, K Mankia, L Duquenne, E Cipolletta, R J Wakefield, L Garcia-Montoya, J L Nam, P Emery*
- 908** Ultrasound Doppler and tenosynovial fluid analysis in tenosynovitis  
*F Aslam, B R England, A Cannella, V Sharp, L Kao, J Arnason, J Albayda, C Bakewell, S Sanghvi, R Fairchild, K D Torralba, A Evangelisto, P J DeMarco, N Bethina, E Y Kissin*

**Spondyloarthritis**

- 914** Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?  
*G T Jones, L E Dean, E Pathan, R J Hollick, G J Macfarlane*
- 920** Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction  
*R BM Landewé, D van der Heijde, M Dougados, X Baraliakos, F E Van den Bosch, K Gaffney, L Bauer, B Hoepken, O R Davies, N de Peyrecave, K Thomas, L Gensler*

**MORE CONTENTS ►**

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008  
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 929** High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics



EDITOR'S CHOICE

*T Renson, A Depicker, A-S De Craemer, L Deroo, G Varkas, M de Hooge, P Caron, L Jans, N Herregods, I Dehaene, G Vandenberghe, K Roelens, F E Van den Bosch, D Elewaut*

- 935** Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria

*W P Maksymowycz, S J Pedersen, U Weber, X Baraliakos, P M Machado, I Eshed, M de Hooge, J Sieper, S Wichuk, M Rudwaleit, D van der Heijde, R B M Landewé, D Poddubnyy, M Ostergaard, R G W Lambert*

### Systemic lupus erythematosus

- 943** Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort



EDITOR'S CHOICE

*F Saccon, M Zen, M Gatto, D P E Margiotta, A Afeltra, F Ceccarelli, F Conti, A Bortoluzzi, M Govoni, G Frontini, G Moroni, F Dall'Ara, A Tincani, V Signorini, M Mosca, A C Frigo, L Iaccarino, A Doria*

### Vasculitis

- 951** Targeting JAK/STAT pathway in Takayasu's arteritis

*P Régnier, A Le Joncour, A Maciejewski-Duval, A-C Desbois, C Comarmond, M Rosenzweig, D Klatzmann, P Cacoub, D Saadoun*

### Autoinflammatory disorders

- 960** Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever



OPEN ACCESS

*H Van Gorp, L Huang, P Saavedra, M Vuylsteke, T Asaoka, G Prencipe, A Insalaco, B Ogunjimi, J Jeyaratnam, I Cataldo, P Jacques, K Vermaelen, M Dullaers, R Joos, V Sabato, A Stella, J Frenkel, F De Benedetti, J Dehoorne, F Haerynck, G Calamita, P Portincasa, M Lamkanfi*

### Paediatric rheumatology

- 969** Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis
- A Klein, K Minden, A Hospach, I Foeldvari, F Weller-Heinemann, R Trauzeddel, H-I Huppertz, G Horneff*

### Osteoarthritis

- 975** BCP crystals promote chondrocyte hypertrophic differentiation in OA cartilage by sequestering Wnt3a

*J Bertrand, T Kräfft, T Gronau, J Sherwood, F Rutsch, F Lioté, F Dell'Accio, C H Lohmann, M Bollmann, A Held, T Pap*

### Letters

- 986** Hope

*K Sheth*

- 986** Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study

*C Salvarani, G Bajocchi, P Mancuso, E Galli, F Muratore, L Boiardi, M Catanoso, N Pipitone, G Cassone, N Girolimetto, S Croci, L Cimino, F Gradellini, M Beltrami, V Di Lernia, G Dolci, M Massari, A M Marata, M Costantini, P Giorgi Rossi*

- 988** Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies



OPEN ACCESS

*C Sanchez-Piedra, C Diaz-Torne, J Manero, J M Pego-Reigosa, Í Rúa-Figueroa, M A Gonzalez-Gay, J Gomez-Reino, J M Alvaro-Gracia, On behalf of the BIOBADASER study group*

### Electronic pages

- e79** TARA study: a new perspective on tapering drugs in RA

*D Mishra, A Chattopadhyay, S Jain, V Dhir*

- e80** Response to: 'TARA Study: a new perspective on tapering drugs in RA' by Mishra *et al*

*E van Mulligen, J M W Hazes, A E A M Weel, P H P de Jong*

- e81** Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study

*H Marotte, M Rinaudo-Gaujous, C Petiet, B Fautrel, S Paul*

- e82** Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte *et al*

*M J l'Ami, C L Kriekaert, M T Nurmohamed, R F van Vollenhoven, T Rispen, M Boers, G J Wolbink*

- e83** Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning?

*Z Deng, H Liu, W Lu*

- e84** Response to: 'Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning?' by Deng *et al*  
*K Mankia, M-A D'Agostino, J Murillo-González, A Grainger, P Emery*
- e85** Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco *et al*  
*J Knitza, L Cavagna, G Schett, J H W Distler*
- e86** Response to: 'Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco *et al*' by Knitza *et al*  
*A Tjärnlund, I E Lundberg*
- e87** Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco *et al* by Knitza *et al*  
*M Greco, M<sup>a</sup> J García de Yébenes, I Alarcón, A M Brandy-García, Í Rúa-Figueroa, E Loza, L Carmona*
- e88** Can IL-1 be used as a target for osteoarthritis?  
*C Cheng, J Tian, F Zhang*
- e89** Response to: 'Can IL-1 be used as a target for osteoarthritis?' by Cheng *et al*  
*M Kloppenburg, M Levesque*